Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography

ObjectiveThe biological significance of [11C]choline (CHO) uptake in human tumours is unclear and probably linked to choline kinase-&agr; (CHK&agr;) expression and cell proliferation. We directly compared CHO with [18F]fluorothymidine (FLT), an imaging biomarker of proliferation, by positron emission tomography (PET) in patients with breast cancer to investigate whether cell proliferation is an important determinant of CHO uptake. Furthermore, we evaluated CHK&agr; and the Ki67-labelling index (LIKi67) in tumour biopsies. MethodsSequential CHO-PET and FLT-PET within the same imaging session were performed in 21 patients with oestrogen receptor (ER)-positive breast cancer (28 lesions). Average and maximum CHO standardized uptake values (SUV) at 60 min: SUV60,av, and SUV60,max, and the rate constant of net irreversible uptake, Ki, were compared with FLT uptake at 60 min: SUV60,av and SUV60,max. Biopsies were stained for CHK&agr; and LIKi67 in eight cases. ResultsTumours were equally visible on CHO-PET and FLT-PET imaging. Tumour CHO-PET strongly correlated with FLT imaging variables (Pearson’s r=0.83; P<0.0001 for CHO-SUV60,max vs. FLT-SUV60,max). A statistically significant association was found between CHO-PET variables and categorical scores of cytoplasmic CHK&agr; intensity and between FLT-PET and LIKi67 (P<0.05, one-way analysis of variance). ConclusionCholine metabolism and proliferation as assessed by PET were correlated in ER-positive breast cancer, indicating that high CHO uptake is a measure of cellular proliferation in this setting. CHO uptake was also found to be related to cytoplasmic CHK&agr; expression.

[1]  Hyunjin Park,et al.  Detection of Aggressive Primary Prostate Cancer with 11C-Choline PET/CT Using Multimodality Fusion Techniques , 2009, Journal of Nuclear Medicine.

[2]  S. Shousha,et al.  [ 11 C]Choline Positron Emission Tomography in Estrogen Receptor – Positive Breast Cancer , 2009 .

[3]  O. Muzik,et al.  Analysis and Reproducibility of 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[4]  Marcin Skrzypski,et al.  Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. , 2007, The Lancet. Oncology.

[5]  G. Hutchins,et al.  Evaluation of [11C]hemicholinium-15 and [18F]hemicholinium-15 as new potential PET tracers for the high-affinity choline uptake system in the heart. , 2007, Bioorganic & Medicinal Chemistry.

[6]  M. Bakovic,et al.  Choline Transport for Phospholipid Synthesis , 2006 .

[7]  V. Raman,et al.  RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. , 2005, Cancer research.

[8]  S. Shousha,et al.  Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.

[9]  Bruce D Cheson,et al.  Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.

[10]  J. Pruim,et al.  In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Tim A D Smith,et al.  [methyl-3H]Choline incorporation into MCF7 tumour cells: correlation with proliferation , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  G Lucignani,et al.  The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective , 2004, Nuclear medicine communications.

[13]  G. Carman,et al.  Phosphorylation of Saccharomyces cerevisiae CTP Synthetase at Ser424 by Protein Kinases A and C Regulates Phosphatidylcholine Synthesis by the CDP-choline Pathway* , 2003, Journal of Biological Chemistry.

[14]  S. Osman,et al.  Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin , 2002, British Journal of Cancer.

[15]  G. Carman,et al.  Phosphorylation of Saccharomyces cerevisiae Choline Kinase on Ser30 and Ser85 by Protein Kinase A Regulates Phosphatidylcholine Synthesis by the CDP-choline Pathway* , 2002, The Journal of Biological Chemistry.

[16]  Jose M. Silva,et al.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.

[17]  H. Degani,et al.  Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. , 2002, Cancer research.

[18]  U. Haberkorn,et al.  Synthesis of 3′‐deoxy‐3′‐[18F]fluoro‐thymidine with 2,3′‐anhydro‐5′‐O‐(4,4′‐dimethoxytrityl)‐thymidine , 2000 .

[19]  A. Bogni,et al.  [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline , 2000 .

[20]  J. Lacal,et al.  In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. , 1999, Cancer research.

[21]  D. Mankoff,et al.  A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  C. Kent,et al.  Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. , 1995, Archives of biochemistry and biophysics.

[23]  M. Bilous,et al.  A comparison between Ki‐67 antibody reactivity and other pathological variables in breast carcinoma , 1991, Pathology.